Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
A new Johns Hopkins study shows that data gathered from wearable activity trackers can be used to obtain several metrics associated with the user's general physical health and cardiovascular health status.
Earlier detection of pulmonary hypertension in the community and expedited referral of high-risk or complex patients are recommended in the European Society of Cardiology (ESC) and European Respiratory Society (ERS) Guidelines for the diagnosis and treatment of pulmonary hypertension, published online today in European Heart Journal and the European Respiratory Journal.
A new study published in the British Journal of Anaesthesia aimed to determine whether sildenafil could improve gaseous exchange in patients with COVID-19 ARDS with pulmonary hypertension, RV dysfunction, or both.
Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the lungs, in which blood vessels are narrowed, blocked or destroyed, causing the heart to work harder and, in time, result in cardiac weakness and failure.
A recent scientific statement published in Circulation reviewed the current knowledge on COVID-19.
A recent review paper in the journal Frontiers in Physiology discusses the role of leptins in infection with SARS-CoV-2 that triggered the ongoing COVID-19 pandemic.
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that use of platelet inhibitors could be associated with a reduction in the occurrence of digital ulcers, painful sores on the extremities that can progress to gangrene, in people with systemic sclerosis.
By combining computational and experimental approaches, University of Pittsburgh School of Medicine and Prairie View A&M University researchers identified cancer drugs that show promise for treating pulmonary hypertension, or PH, a rare and incurable lung disease.
A new study published in the journal Frontiers of Medicine indicated that Barrett's esophagus (BE) and gastroesophageal reflux disease (GERD) may represent novel comorbidities associated with SARS-CoV-2 disease. A previous study had estimated that in the United States, 5.6% of adults have BE, a disease where esophageal squamous mucosa gets damaged by GERD.
Portopulmonary hypertension (PoPH) is a form of pulmonary arterial hypertension (PAH). PoPH occurs in approximately 15% of patients with PAH, and is reportedly found in 2-6% of patients with portal hypertension and 1-2% of patients with liver cirrhosis according to studies from Europe and America.
Screening for a sometimes fatal condition among patients with a rare autoimmune disease could soon - thanks to a computer algorithm - become even more accurate.
A new study published on the preprint server bioRxiv in October 2020 shows that vascular cells in the lung tissue begin to secrete signaling growth factors when exposed to just the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), without the rest of the viral components.
The COVID-19 pandemic has increasing numbers of doctors caring for patients virtually. While critical to protecting patient health during a pandemic, however, virtual care presents unique challenges, especially when it comes to diagnosis.
Biomedical engineers at Duke University have shown that the efficacy of a two-pronged type 2 diabetes treatment increases when the drugs are linked by a heat-sensitive tether rather than simply concurrently administered.
Pulmonary arterial hypertension is a rare--albeit deadly--disease that affects the arteries of the lung. In PAH, abnormal growth of cells of the vascular media--or the elastic wall--of the pulmonary arteries, called pulmonary arterial smooth muscle cells, results in thickening of the walls.
Pulmonary arterial hypertension (PAH) is an insidious disease. Symptoms may begin slowly, and even before they appear, extensive damage has caused the obstruction of small arteries leading to increased blood pressure in the lungs.
Pulmonary hypertension is a serious problem associated with a wide variety of lung diseases, which can lead to right ventricular dysfunction and death.
Sygnature Discovery, a leading independent integrated drug discovery and pre-clinical services company, is supporting Professor Sachin Gupte, a pharmacologist at the New York Medical College, in his endeavours to find a drug treatment for the lung damage that can result from Covid-19 infection.
Andrea Amelse knows hand-washing.
APEIRON Biologics AG, a biotechnology company with an approved product on the market as well as a broad preclinical and clinical pipeline, today announced the launch of a Pilot investigator-initiated clinical trial with APN01, a recombinant human angiotensin-converting enzyme 2, to treat patients with severe coronavirus infection in the People's Republic of China.